Atrial Fibrillation pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

July 2020 | 121 pages | ID: A0155572B592EN
VPAResearch

Abstracts

2020 Atrial Fibrillation PIPELINE HIGHLIGHTS
Atrial Fibrillation is one of the widely researched conditions during 2020 with 23 companies actively focusing on realizing pipeline’s potential. Development of Atrial Fibrillation medicines is identified as integral to the strategy of the majority of companies operating in the industry.
Global Atrial Fibrillation market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Atrial Fibrillation.

Good progress is anticipated during 2020 and 2021 with Atrial Fibrillation pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Atrial Fibrillation pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.
Atrial Fibrillation DRUG DEVELOPMENT PIPELINE OVERVIEW
The “Atrial Fibrillation pipeline Research Monitor, 2020” report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
This Atrial Fibrillation pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Atrial Fibrillation presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Atrial Fibrillation pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.
Atrial Fibrillation DRUG PROFILES
Atrial Fibrillation development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

• Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.
• Phase of development
• Mechanism of Action
• Route of Administration
• Companies involved including originator, licensing companies, developer, investors, and others
• New molecular entity details
• Orphan drug designation and other special status provided by regulators

Atrial Fibrillation COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Atrial Fibrillation drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Atrial Fibrillation. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 23 Atrial Fibrillation companies including company overview, key snapshot, contact information, and their strategies on accelerating Atrial Fibrillation pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Acesion Pharma, Allergan Plc, Allosteros Therapeutics Inc, AnaBios Corporation, ARCA biopharma Inc, Armaron Bio Pty Ltd, Correvio Pharma Corp., Daiichi Sankyo Co Ltd, Espero BioPharma Inc, G3 Pharmaceuticals Inc, Gilead Sciences Inc, HUYA Bioscience International, Hyloris Pharmaceuticals SA , InCarda Therapeutics Inc, Merck & Co Inc, Merz Pharma GmbH & Co KgaA, Milestone Pharmaceuticals Inc, Nissan Chemical Industries Ltd, OMEICOS Therapeutics GmbH, Rhythm Therapeutics Inc, The Geneva Biotech Center SA, Toa Eiyo Ltd, Verseon Corp

REASONS TO BUY

• The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.
• This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data
• Buyers can identify most promising drug candidates for treatment of Atrial Fibrillation
• It allows users to strengthen their pipeline through acquisitions, licensing and collaborations
• Users can estimate possible delays in the delivery of pipeline or launch of new products
• Stay ahead of competition through understanding their pipeline progression, strategies and outlook
• The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.
• Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO ATRIAL FIBRILLATION

1.1 Atrial Fibrillation- Disease overview
1.2 Atrial Fibrillation- Market Size
1.3 Atrial Fibrillation- Companies Involved

2. ATRIAL FIBRILLATION PIPELINE SNAPSHOT- 2020

2.1 Atrial Fibrillation Pipeline by Phase
2.2 Atrial Fibrillation Pipeline by Mechanism of Action
2.3 Atrial Fibrillation Pipeline by Route of Administration
2.4 Atrial Fibrillation Pipeline- New Molecular Entities
2.5 Atrial Fibrillation Pipeline- Orphan Drug Designation/ Special Designation

3. ATRIAL FIBRILLATION DRUG PROFILES

3.1 Current Status
3.2 Atrial Fibrillation Drug Snapshot
3.3 Atrial Fibrillation Therapeutic Candidates- Originator/Licensor
3.4 Route of Administration
3.5 Mechanism of Action
3.6 NME
4.1 Acesion Pharma Atrial Fibrillation Pipeline Insights and Clinical Trials
4.2 Allergan Plc Atrial Fibrillation Pipeline Insights and Clinical Trials
4.3 Allosteros Therapeutics Inc Atrial Fibrillation Pipeline Insights and Clinical Trials
4.4 AnaBios Corporation Atrial Fibrillation Pipeline Insights and Clinical Trials
4.5 ARCA biopharma Inc Atrial Fibrillation Pipeline Insights and Clinical Trials
4.6 Armaron Bio Pty Ltd Atrial Fibrillation Pipeline Insights and Clinical Trials
4.7 Correvio Pharma Corp. Atrial Fibrillation Pipeline Insights and Clinical Trials
4.8 Daiichi Sankyo Co Ltd Atrial Fibrillation Pipeline Insights and Clinical Trials
4.9 Espero BioPharma Inc Atrial Fibrillation Pipeline Insights and Clinical Trials
4.10 G3 Pharmaceuticals Inc Atrial Fibrillation Pipeline Insights and Clinical Trials
4.11 Gilead Sciences Inc Atrial Fibrillation Pipeline Insights and Clinical Trials
4.12 HUYA Bioscience International Atrial Fibrillation Pipeline Insights and Clinical Trials
4.13 Hyloris Pharmaceuticals SA Atrial Fibrillation Pipeline Insights and Clinical Trials
4.14 InCarda Therapeutics Inc Atrial Fibrillation Pipeline Insights and Clinical Trials
4.15 Merck & Co Inc Atrial Fibrillation Pipeline Insights and Clinical Trials
4.16 Merz Pharma GmbH & Co KgaA Atrial Fibrillation Pipeline Insights and Clinical Trials
4.17 Milestone Pharmaceuticals Inc Atrial Fibrillation Pipeline Insights and Clinical Trials
4.18 Nissan Chemical Industries Ltd Atrial Fibrillation Pipeline Insights and Clinical Trials
4.19 OMEICOS Therapeutics GmbH Atrial Fibrillation Pipeline Insights and Clinical Trials
4.20 Rhythm Therapeutics Inc Atrial Fibrillation Pipeline Insights and Clinical Trials
4.21 The Geneva Biotech Center SA Atrial Fibrillation Pipeline Insights and Clinical Trials
4.22 Toa Eiyo Ltd Atrial Fibrillation Pipeline Insights and Clinical Trials
4.23 Verseon Corp Atrial Fibrillation Pipeline Insights and Clinical Trials

5. ATRIAL FIBRILLATION MARKET NEWS AND UPDATES

6. APPENDIX

6.1 Sources and Methodology
6.2 Contact Information